Delving into the Latest Updates on Tisagenlecleucel with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

Adoptive immunotherapy agent CTL019, Anti-CD19-CAR transduced T cells, Anti-CD19-chim

+ [9]

Target

CD19

Mechanism

CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Pre B-cell acute lymphoblastic leukemiaFollicular LymphomaDiffuse large B-cell lymphoma recurrent+ [20]

Inactive Indication

B lymphoblastic leukemia lymphomaB-cell lymphoma refractoryCD19 positive Acute Lymphoblastic Leukemia+ [3]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Pharmaceuticals Corp.Novartis Pharma AG

Novartis AG

+ [4]

Inactive Organization

Shanghai Cellular Biopharmaceutical Group Ltd.

Fujian Medical UniversityAbramson Cancer Center

Drug Highest PhaseApproved

First Approval Date

US (30 Aug 2017),

CD19-positive B-cell Precursor acute lymphoblastic leukemiaDiffuse Large B-Cell LymphomaHigh grade B-cell lymphoma

RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Regenerative Medicine Advanced Therapy (US)

Login to view First Approval Timeline

Gene Sequence

Sequence Code 631391916

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults with relapsed or refractory B-cell leukemia.

Start Date13 May 2024

Sponsor / Collaborator

Stanford University

NCT04419909 / Not yet recruitingPhase 1IIT

Retreatment With CTL019/CTL119 in Patients With Late Relapse of B-Cell Lymphomas

This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.

Start Date01 May 2024

Sponsor / Collaborator

University of Pennsylvania

NCT05541341 / RecruitingNot Applicable

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies: a 15-year Prospective Registry Study on Three Cohorts.

This will be a multicenter, national, non-interventional, prospective cohort study

Start Date24 Nov 2023

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with Tisagenlecleucel

Login to view more data

100 Translational Medicine associated with Tisagenlecleucel

Login to view more data

100 Patents (Medical) associated with Tisagenlecleucel

Login to view more data

515

Literatures (Medical) associated with Tisagenlecleucel

01 May 2024·PharmacoEconomics

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA

Article

Author: Shapouri, Sheila ; Matasar, Matthew ; Parisé, Hélène ; Bercaw, Eric ; Wu, Mei ; Kim, Eunice ; Lin, Shih-Wen

OBJECTIVE:

This study aimed to assess the budget impact of introducing fixed-duration mosunetuzumab as a treatment option for adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies and to estimate the total cumulative costs per patient in the USA.

METHODS:

A 3-year budget impact model was developed for a hypothetical 1-million-member cohort enrolled in a mixed commercial/Medicare health plan. Comparators were: axicabtagene ciloleucel, tisagenlecleucel, tazemetostat, rituximab plus lenalidomide, copanlisib, and older therapies (rituximab or obinutuzumab ± chemotherapy). Costs per patient comprised treatment-associated costs including the drug, its administration, adverse events, and routine care. Dosing and safety data were ascertained from respective package inserts and clinical trial data. Drug costs (March 2023) were estimated based on the average wholesale acquisition cost reported in AnalySource^®, and all other costs were based on published sources and inflated to 2022 US dollars. Market shares were obtained from Genentech internal projections and expert opinion. Budget impact outcomes were presented on a per-member per-month basis.

RESULTS:

Compared with a scenario without mosunetuzumab, its introduction over 3 years resulted in a budget increase of $69,812 (1% increase) and an average per-member per-month budget impact of $0.0019. Among the newer therapies, mosunetuzumab had the second-lowest cumulative per patient cost (mosunetuzumab = $202,039; axicabtagene ciloleucel = $505,845; tisagenlecleucel = $476,293; rituximab plus lenalidomide = $263,520; tazemetostat = $250,665; copanlisib = $127,293) and drug costs, and its introduction only increased total drug costs by 0.1%. By year 3, the cumulative difference in the per patient cost with mosunetuzumab was -$303,805 versus axicabtagene ciloleucel, -$274,254 versus tisagenlecleucel, -$61,481 versus rituximab plus lenalidomide, -$48,625 versus tazemetostat, and $74,747 versus copanlisib. Older therapies were less costly with 3-year cumulative costs that ranged from $36,512 to $147,885.

CONCLUSIONS:

Over 3 years, the estimated cumulative per patient cost of mosunetuzumab is lower than most available newer therapies, resulting in a small increase in the budget after its formulary adoption for the treatment of relapsed or refractory follicular lymphoma.

01 Jan 2024·Transplantation and cellular therapy

Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia

Article

Author: Moskop, Amy ; Talano, Julie-An ; Schiff, Deborah ; Rossoff, Jenna ; McNerney, Kevin O ; Winestone, Lena E ; Modi, Arunkumar ; Laetsch, Theodore W ; Verneris, Michael R ; Schultz, Liora ; Baggott, Christina

Treatment with tisagenlecleucel (tisa-cel) achieves excellent complete remission rates in children and young adults with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL), but approximately 50% maintain long-term remission. Consolidative hematopoietic stem cell transplantation (cHSCT) is a potential strategy to reduce relapse risk, but it carries substantial short- and long-term toxicities. Additionally, several strategies for management of B cell recovery (BCR) and next-generation sequencing (NGS) positivity post-tisa-cel exist, without an accepted standard. We hypothesized that practice preferences surrounding cHSCT, as well as management of BCR and NGS positivity, varies across tisa-cel-prescribing physicians and sought to characterize current practice preferences. A survey focusing on preferences regarding the use of cHSCT, management of BCR, and NGS positivity was distributed to physicians who prescribe tisa-cel for children and young adults with B-ALL. Responses were collected from August 2022 to April 2023. Fifty-nine unique responses were collected across 43 institutions. All respondents prescribed tisa-cel for children and young adults. The clinical focus of respondents was HSCT in 71%, followed by leukemia/lymphoma in 24%. For HSCT-naive patients receiving tisa-cel, 57% of respondents indicated they made individualized decisions for cHSCT based on patient factors, whereas 22% indicated they would avoid cHSCT and 21% indicated they would pursue cHSCT when feasible. Certain factors influenced >50% of respondents towards recommending cHSCT (either an increased likelihood of recommending or always recommending), including preinfusion disease burden >25%, primary refractory B-ALL, M3 bone marrow following reinduction for relapse, KMT2A-rearranged B-ALL, history of blinatumomab nonresponse, and HSCT-naive status. Most respondents indicated they would pursue HSCT for HSCT-naive, total body irradiation (TBI) recipients with BCR before 6 months post-tisa-cel or with NGS positivity at 1 or 3 months post-tisa-cel, although there was variability in responses regarding whether to proceed to HSCT directly or provide intervening therapy prior to HSCT. Fewer respondents recommended HSCT for BCR or NGS positivity in patients with a history of HSCT, in noncandidates for TBI, and in patients with trisomy 21. The results of this survey indicate there exists significant practice variability regarding the use of cHSCT, as well as interventions for post-tisa-cel BCR or NGS positivity. These results highlight areas in which ongoing clinical trials could inform more standardized practice.

01 Apr 2024·Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology

Review

Author: Cocks, Kim ; Bennett, Bryan ; Dhanda, Devender ; Clarke, Nathan A ; Braverman, Julia ; Worthy, Gill ; Shaw, James W

OBJECTIVES:

This literature review provides an overview of meaningful change thresholds for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) and the Functional Assessment of Cancer Therapy - General (FACT-G) used across hematological cancers and solid tumors (melanoma, lung, bladder, and prostate).

METHODS:

Embase, MEDLINE, and PubMed were searched to identify relevant oncology publications from 2016 to 2021. Label claims from the US Food and Drug Administration and the European Medicines Agency for 7 recently approved drugs (pembrolizumab, atezolizumab, glasdegib, gilteritinib, tisagenlecleucel, axicabtagene ciloleucel, and daratumumab plus hyaluronidase-fihj) were reviewed.

RESULTS:

Publications providing guidance on meaningful change thresholds for the QLQ-C30 displayed a growing trend away from broad "legacy" thresholds of 10 points for all QLQ-C30 scales), toward deriving "contemporary" thresholds (eg, subscale specific, population specific). Contemporary publications generally provide guidance on selecting thresholds for specific scales that account for improved or worsening thresholds (eg, QLQ-C30 subscales). This trend was not clear for FACT-G, with less new guidance available. Most clinical trials used in regulatory label submissions have used thresholds of 10 points for the QLQ-C30 subscales and 3 to 7 points for the FACT-G total score. Despite the availability of more recent guidelines, contemporary meaningful change thresholds seem slow to emerge in the published literature and regulatory labels.

CONCLUSIONS:

Trialists should consider using contemporary thresholds, rather than legacy thresholds, for QLQ-C30 endpoints. Thresholds derived for a similar patient-population should be used where available. Further work is required to provide these across a broader range of cancer sites.

155

News (Medical) associated with Tisagenlecleucel

17 Jun 2024

·www.pharmaceutical-technology.com

APAC leaps ahead in adoptive cell therapy space

Caption: Credit: Scotty Chung-Siu via GlobalData. The APAC region is the leading area for the clinical development of adoptive cell therapies. The Asia Pacific (APAC) region is leading the charge for adoptive cell therapy studies , says Scotty Chung-Siu, a managing analyst at GlobalData. At the Annual Outsourcing in Clinical Trials conference , held from 11-12 June, Chung-Siu led a comprehensive session on adoptive cell therapies, giving an overview of the space to the audience of clinical trial professionals. Chung Siu cited a GlobalData report that demonstrated that the number of ongoing single-country adoptive cell therapy studies in the APAC region has reached approximately twelve times the number of trials in Europe. He also highlighted that overall, there are 1,023 single country adoptive cell therapy clinical studies being run in the APAC region compared to 476 in North America. GlobalData is the parent company of Pharmaceutical Technology . Adoptive cell therapies are immunotherapies that use engineered cells to trigger a patient’s immune system to treat a condition. The three main types of adoptive cell therapies are tumour-infiltrating lymphocyte (TIL) immunotherapy, natural killer (NK) cell immunotherapy, and T cell immunotherapies. The last category includes several modalities such as chimeric antigen T (CAR-T) cell therapies , natural killer T cells, regulatory T cells, and T cell receptor (TCR) therapies. See Also: AZD-1705 by AstraZeneca for Dyslipidemia: Likelihood of Approval Sabestomig by AstraZeneca for Crohn’s Disease (Regional Enteritis): Likelihood of Approval Blockbuster adoptive cell therapies such as Novartis ’ CAR-T therapy Kymriah (tisagenlecleucel), and Gilead Sciences ’ and Daiichi Sankyo ’s Yescarta (axicabtagene ciloleucel) are commercially available in some Asian countries, with the former company placing cell therapy manufacturing sites in Japan in 2020. A February 2024 paper published in the Blood Cell Therapy journal, reported that Asia has driven 70% of global economic growth in the last two years, and estimated a compound annual growth rate for CAR-T adoption in Asia of 40%. Chung Siu also pointed to the Bongguan, Hebei, China-headquartered Hebei Senlang Biotechnology and the Chongqing, China-based Chongqin Precision Biotech as some of the top industry sponsors, leading with 34 and 32 adoptive cell therapy trials, respectively. The London conference held sessions discussing a wide range of topics in the field of clinical research, ranging from the UK clinical trial landscape to the use of AI in clinical trials. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Cell TherapyImmunotherapyClinical Study

13 Jun 2024

·www.echemi.com

Top 10 Global Revenue for Cell and Gene Therapies

According to the latest statistics, cell and gene therapies are rapidly emerging as a hot topic in the pharmaceutical field due to their unique therapeutic advantages. A recent report has revealed the top 10 best-selling cell and gene therapy products globally in 2023. At the top of the sales ranking is Yescarta, Gilead's CAR-T cell therapy product, which leads the global CAR-T cell therapy market with sales of $1.498 billion, making it the overall sales champion in the cell and gene therapy field. Closely following are two products from Novartis, Zolgensma and Kymriah, which generated sales of $1.214 billion and $508 million, respectively, ranking second and third. In addition, several other products that made it to the TOP 10 also performed remarkably well, including Carvykti co-developed by Johnson & Johnson and Legend Biotech, Abecma co-launched by BMS and 2seventy bio, and Tecartus from Kite Pharma. It's worth mentioning that if the two antisense oligonucleotide (ASO) therapies for Duchenne muscular dystrophy, Exondys 51 and Amondys 45, developed by Sarepta Therapeutics, were included in the ranking, their 2023 sales of $540 million and $270 million, respectively, would also place them among the top ten. Looking at the sales ranking, CAR-T cell therapies occupy half of the market, fully demonstrating their outstanding position in the treatment of malignant hematological cancers. Meanwhile, gene therapies based on viral vectors, such as Zolgensma and Luxturna, have also shown impressive market performance. Looking forward, with the continuous emergence and launch of more innovative therapies, the cell and gene therapy field will embrace a broader development prospect and unlimited market potential. Menarini Group, as a leading pharmaceutical company in the Italian industry, has weathered 140 years of storms and emerged as an important force in the European and global pharmaceutical industry, thanks to its deep accumulation and excellent technology in the biopharmaceutical field. As a pharmaceutical giant with unique technology, products, and a huge R&D system, Menarini has always focused on the research and development of drugs for cardiovascular diseases, inflammatory pain, gastrointestinal diseases, oncology, and metabolic diseases. Headquartered in the historic city of Florence, the company has a team of over 17,700 excellent employees and operates in more than 140 countries around the world, with numerous subsidiaries, distributors, and franchisees. In recent years, Menarini has actively expanded its international business footprint and strengthened and expanded its position in the global market through a series of strategic acquisitions and collaborations. In the fields of oncology and infectious diseases, Menarini, with its rich product line and innovative technology, has provided many high-quality treatment options for patients worldwide. Take Tagraxofusp as an example, it is the first approved drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the first approved CD123-targeted drug, which has brought unprecedented hope for the clinical treatment of BPDCN patients. Overall, Menarini, with its 140-year deep accumulation and the spirit of continuous innovation, has achieved remarkable results in the fields of oncology and infectious diseases, and continues to provide patients with better treatment options. At the same time, the company also demonstrates strong competitiveness and broad development prospects in the international market.

Drug ApprovalAcquisitionGene TherapyCell TherapyImmunotherapy

13 Jun 2024

·www.biospace.com

Secondary Cancer Risk Is Low After CAR T Cell Treatment: Stanford Study

Pictured: 3D illustration of a CAR-T cell attacking a cancer cell/iStock, Meletios Verras Despite warnings about the drug class from the FDA, a large study led by Stanford Medicine has found that CAR-T cell therapies carry only a low risk of secondary malignancies. The results, published Wednesday in The New England Journal of Medicine, come from a review of 724 patients who had undergone CAR-T therapies at Stanford Health Care between 2016 and 2024. Overall, the study found that secondary cancers arose in approximately 6.5% of patients over a median follow-up period of three years. According to Stanford’s announcement on Wednesday, this incidence rate was “roughly similar” to patients who had been treated instead with stem cell therapy. The study identified one patient who died due to a secondary T-cell cancer, though Stanford researchers contend this was likely caused by the immunosuppression associated with CAR-T therapies, rather than a mis-insertion of the gene for the CAR construct during the preparation of the treatment. Deep profiling of both the original and secondary cancers found that they had “distinct immunophenotypes and genomic pro ” according to researchers, suggesting that that the CAR-T therapy was not responsible for the secondary malignancy. “These results may help researchers focus on the immune suppression that can precede and often follows CAR-T therapy,” David Miklos, co-senior author of the study and chief of bone marrow transplantation and cell therapy at Stanford, said in a statement. Understanding how immunosuppression aggravates cancer risk after CAR-T treatment is especially important “as the CAR-T cell field pivots from treating high-risk, refractory blood cancers to lower risk, but clinically important, disorders including autoimmune diseases,” Miklos said. Stanford’s findings echo that of Penn Medicine, which in January 2024 published a paper in Nature Medicine that also found a low risk of secondary cancers after CAR-T treatment. The Penn researchers used a smaller sample size—449 patients—but their figures were similar: Over a median follow-up of 10.3 months, only 16 patients developed secondary cancers, most of which were solid tumors such as skin and prostate cancer. There was only one case of secondary T-cell lymphoma, which showed only “very low” levels of the CAR transgene. The respective findings from Stanford and Penn could help allay some concerns about the safety of CAR-T therapies. In November 2023, the FDA announced that it was investigating the drug class after it identified cases of secondary malignancies in patients who had received approved CAR-T products. The probe pushed the regulator in April 2024 to require a class-wide black box warning flagging the risk. All six commercially available CAR-T therapies were impacted including Gilead’s Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel), Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel), Novartis’ Kymriah (tisagenlecleucel) and Johnson & Johnson’s Carvykti (ciltacabtagene autoleucel). Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

ImmunotherapyCell TherapyClinical Result

100 Deals associated with Tisagenlecleucel

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB13881

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pre B-cell acute lymphoblastic leukemia	US	Novartis Pharmaceuticals Corp.	27 Jun 2024
Follicular Lymphoma	US	Novartis Pharmaceuticals Corp.	26 May 2022
Diffuse large B-cell lymphoma recurrent	KR	Novartis AG	05 Mar 2021
Diffuse large B-cell lymphoma refractory	KR	Novartis AG	05 Mar 2021
Recurrent B Acute Lymphoblastic Leukemia	KR	Novartis AG	05 Mar 2021
Recurrent Follicular Lymphoma	KR	Novartis AG	05 Mar 2021
Refractory B Acute Lymphoblastic Leukemia	KR	Novartis AG	05 Mar 2021
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	CH	Novartis AG	18 Oct 2018
Acute Lymphoblastic Leukemia	EU	Novartis Europharm Ltd.	23 Aug 2018
Acute Lymphoblastic Leukemia	IS	Novartis Europharm Ltd.	23 Aug 2018
Acute Lymphoblastic Leukemia	LI	Novartis Europharm Ltd.	23 Aug 2018
Acute Lymphoblastic Leukemia	NO	Novartis Europharm Ltd.	23 Aug 2018
Refractory Follicular Lymphoma	EU	Novartis Europharm Ltd.	23 Aug 2018
Refractory Follicular Lymphoma	IS	Novartis Europharm Ltd.	23 Aug 2018
Refractory Follicular Lymphoma	LI	Novartis Europharm Ltd.	23 Aug 2018
Refractory Follicular Lymphoma	NO	Novartis Europharm Ltd.	23 Aug 2018
Large B-cell lymphoma	US	Novartis Pharmaceuticals Corp.	13 Apr 2018
CD19-positive B-cell Precursor acute lymphoblastic leukemia	US	Novartis Pharmaceuticals Corp.	30 Aug 2017
Diffuse Large B-Cell Lymphoma	US	Novartis Pharmaceuticals Corp.	30 Aug 2017
High grade B-cell lymphoma	US	Novartis Pharmaceuticals Corp.	30 Aug 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	US	China Novartis Institutes for BioMedical Research Co., Ltd.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	US	Novartis Pharmaceuticals Corp.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	US	Novartis Pharma AG	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	CN	Novartis Pharmaceuticals Corp.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	JP	Novartis Pharma AG	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	JP	Novartis Pharmaceuticals Corp.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	JP	China Novartis Institutes for BioMedical Research Co., Ltd.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	AU	Novartis Pharmaceuticals Corp.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	AU	China Novartis Institutes for BioMedical Research Co., Ltd.	07 May 2019
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 3	AU	Novartis Pharma AG	07 May 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ELIANA trial (ASCO2024)	Not Applicable	Recurrent B Acute Lymphoblastic Leukemia CD19	974	Tisagenlecleucel	skiegpubmi(ndobztznzu) = jmyusndmyl pdrjxqirsz (ulrasfqwig, 61 - 71) View more	Positive	24 May 2024
NCT03568461 (ELARA, EHA2024) Manual	Phase 2	Follicular Lymphoma Third line	97	Tisagenlecleucel infusion	hhpfjfddvd(jtrspqarxh) = vfhvpdpasx qhlwutuztk (httwyyuptk, 77.5 ~ 92.4) View more	Positive	14 May 2024
NCT02445248 (JULIET, CTgov)	Phase 2	Diffuse large B-cell lymphoma recurrent	115	tisagenlecleucel (Tisagenlecleucel - Main Cohort)	xosglnxcoa(ubztwfrhit) = mvwdhlcluq guufxasewu (sppqrskuah, wtmotjtnax - rrxtwpxuwn) View more	-	18 Apr 2024
NCT02445248 (JULIET, CTgov)	Phase 2	Diffuse large B-cell lymphoma recurrent	115	tisagenlecleucel (Tisagenlecleucel - Cohort A)	fcelkwjizz(gxnbsabphx) = xqtljseqxr bddyiypkzl (oplkysvijg, dbsuficdks - sipscofecz) View more	-	18 Apr 2024
NCT04234061 (TARMAC, Pubmed) Manual	Phase 2	Mantle-Cell Lymphoma	20	CTL019+ibrutinib	ptgvpspnbk(zkhzbxnpea) = yslpwnfjjt huzautjqqw (tlhzxmukbq ) Met View more	-	22 Feb 2024
NCT03568461 (ELARA, Pubmed)	Phase 2	Follicular Lymphoma	97	Tisagenlecleucel infusion (0.6-6×108 CAR+ viable T cells)	ounlulmupm(nycgfdwsjx) = mjuydvnyck bolfhacrpb (gaiqsimplu, 54.3 - 76) View more	-	09 Jan 2024
ASH2023	Not Applicable	Follicular Lymphoma \| refractory acute lymphoid leukemia in relapse \| Diffuse Large B-Cell Lymphoma	-	Tisagenlecleucel	fpjbsfmbhu(ahnsvkmbpi) = wcfctlxaqe wsubzgqxen (lzkvvxzvzu ) View more	-	11 Dec 2023
ASH2023	Not Applicable	Lymphoma	-	Tisagenlecleucel	lnaehandtm(wybtehpztc) = nscipxbama zvtxucnwfe (txtyptoiuf )	-	11 Dec 2023
ASH2023	Not Applicable	Lymphoma	-	Axicabtagene Ciloleucel	lnaehandtm(wybtehpztc) = cdhzhhrgxn zvtxucnwfe (txtyptoiuf )	-	11 Dec 2023
ELARA (ASH2023)	Phase 2	Follicular Lymphoma	97	Tisagenlecleucel	cmknwwxvgt(haiuuudyit) = jzsgpmqhhk utobxphpha (jdhgpqoixb ) View more	-	10 Dec 2023
ASH2023	Not Applicable	Diffuse large B-cell lymphoma recurrent	1,375	Tisagenlecleucel	aswmirsdbq(tevqgoiqxr) = eudrzqtcis syhiqljlak (orrdcmwijp, 41.0 - 53.8) View more	-	10 Dec 2023
ASH2023	Not Applicable	Recurrent Transformed Chronic Lymphocytic Leukemia	48	Tisagenlecleucel	enkwpnmlxx(ilrmoithve) = gtmryaxcht rozzeakbud (kjpuyyslyy, 47.5 - 76.8) View more	Positive	10 Dec 2023